إعلان
إعلان
TVTX
Travere Therapeutics, Inc. Common Stock
39.49
USDبرعاية
+1.28
+3.36%
٠٢ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
39.38
-0.11
-0.27%
تقارير أرباح TVTX
النسبة الإيجابية المفاجئة
TVTX تفوق 16 من 40 آخر التقديرات.
40%
التقرير التالي
بيانات التقرير القادم
١٨ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$145.08M
/-$0.12
التغير الضمني من Q3 25 (Revenue/ EPS)
-12.00%
/-142.86%
التغير الضمني من Q4 24 (Revenue/ EPS)
+93.99%
/-83.56%
Travere Therapeutics, Inc. Common Stock earnings per share and revenue
On ٣٠ أكتوبر ٢٠٢٥, TVTX reported earnings of 0.28 USD per share (EPS) for Q3 25, beating the estimate of -0.21 USD, resulting in a 232.08% surprise. Revenue reached 164.86 مليون, compared to an expected 108.66 مليون, with a 51.71% difference. The market reacted with a +18.58% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 145.08 مليون USD, implying an decrease of -142.86% EPS, and decrease of -12.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
٢٢ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.57
الفعلي
-$0.73
مفاجئة
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
١٩ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.25
الفعلي
-$0.19
مفاجئة
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
What were Travere Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Travere Therapeutics, Inc. Common Stock reported EPS of $0.28, beating estimates by 232.08%, and revenue of $164.86M, 51.71% above expectations.
How did the market react to Travere Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 18.58%, changed from $29.65 before the earnings release to $35.16 the day after.
When is Travere Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ١٨ فبراير ٢٠٢٦.
What are the forecasts for Travere Therapeutics, Inc. Common Stock's next earnings report?
Based on 16
analysts, Travere Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $145.08M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان